| Part1Construction analysis of non-Hodgkin lymphoma subtypesAbstractObjective To understand the pathological type and distribution characteristics of non-Hodgkin lymphoma patients from our hospital according to the WHO2008hemapoietic and lymphoid tissue malignancy classification.Method Collect the clinical data, pathological and immune-phenotyping materials of2019non-Hodgkin lymphoma patients from our hospital dating from January2010to December2013, classify the data according to WHO2008classification criteria, summarize and analyze these materials.Result Within the2019non-Hodgkin lymphoma patients,1290were male (63.9%) and729were female (36.1%), the male/female ratio was1.77:1. For non-Hodgkin lymphoma (NHL), the average age of the patients were53.9y, with the median age being56y. DLBCL was the most common subtype (47.5%) in NHL. For all the non-Hodgkin; lymphoma patients, around90%belongs to stage Ⅲ and Ⅳ. NHL patients of our hospital were mainly from Hangzhou, Shaoxing, Taizhou and Jinhua.Conclusion The incidence of non-Hodgkin Lymphoma is greater in male than in female, NHL favors the middle-aged and the eldly. DLBCL is the most common subtype of NHL. Part2Occupational ultraviolet exposure and risk of Non-Hodgkin’s lymphomas:a meta-analysisAbstractPurpose The purpose was to perform a meta-analysis to summarize the available evidence from case-control studies and cohort study on the inconsistent association between occupational sun exposure and the risk of NHL.Methods We searched PubMed, ISI web of science, the Cochrane Library, EMBASE and reference lists for relevant articles. Study specific odds ratios (ORs) or relative risk (RRs) and95%confidence intervals (CIs) were pooled by using a random-effects model.Results10case-control studies and1cohort study were included in the meta-analysis. Overall, the pooled OR for occupational ultraviolet exposure and NHL risk was1.15(95%CI:0.99,1.32; I2=44.4%). Common subtypes of NHL and ultraviolet exposure had the same results. The pooled OR was1.16,(95%CI:0.90,1.50) for T-NHL;0.79,(95%CI:0.61,1.02) for B-NHL;1.13,(95%CI:0.96,1.34) for CLL;1.25,(95%CI:0.95,1.64) for male;1.49,(95%CI:0.99,2.25) for female.Conclusions Data suggests there had no relationship between occupational ultraviolet exposure and risk of NHL as well as NHL common subtypes. Part3Vitamin D levels and risk of Non-Hodgkin’s lymphomas:a meta-analysisAbstractObjective The objective was to perform a meta-analysis to summarize the available evidence from case-control studies and cohort studies on the association of vitamin D levels and the risk of NHL.Methods We searched PubMed, ISI web of science, the Cochrane Library, EMBASE and reference lists for relevant articles. Study specific odds ratios (ORs) or relative risks (RRs) and95%confidence intervals (CIs) were pooled by using fixed-effect, random-effects, or linear regression dose-responses models.Results12studies (8case-control and4cohort studies) were included in the meta-analysis. The estimated summary OR for highest compared with lowest categories of vitamin D levels was1.01(0.88,1.15; Heterogeneity:I2=43.2%). The pooling ORs of NHL most common subtypes were1.05(0.86,1.28),1.03(0.80,1.33),0.92(0.60,1.41) and1.36(0.76,2.45) for diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), small lymphocytic lymphomas/chronic lymphocytic leukemia (SLL/CLL) and T-cell lymphoma. The results from linear regression dose-responses model was similar (P=0.197).Conclusions Higher vitamin D level does not play a protective role in risk of NHL or common NHL subtypes. Part4Comparison between the efficacy of rituximab plus CHOP and CHOP alone in the treatment of diffuse large B cell lymphomaAbstractObjectives The purpose of this study was to compare the efficacy and survival rate of rituximab plus CHOP and CHOP alone in the treatment of diffuse large B cell lymphoma (DLBCL). Discuss the rituximab and the occurrence of hepatitis between HBsAg positive group and HBsAg negative group.Methods A total of702in-patients diagnosed with DLBCL between January2005and January2015were included in this retrospective study. We scanned the general information of those patience and included377cases. The differences in efficacy and survival rate between the two groups divided according to patients receiving chemotherapy with CHOP or RCHOP were compared. The occurrence of hepatitis between HBsAg positive group and HBsAg negative group were compared too.Results The377patients with DLBCL were divided into2groups:151received CHOP and226received RCHOP. The overall response rates were70.9%in CHOP with62complete response and45partial response,84.1%in RCHOP with136complete response and55partial response. The results showed that the complete response rate and overall response rates in RCHOP were both raise significantly(P=0.0003, P-0.0014). The5-year overall survival rates were81.4±4.0%and56.9±13.4%in RCHOP and CHOP respectively with statistical difference (P=0.01), the5-year progression free survival rates were61.7±5.2%and39.8±7.8%in RCHOP and CHOP respectively with statistical difference (P<0.001).In the subgroup analysis, there were66patients in GCB and184patients in NON-GCB, the5-year overall survival rates and the5-year progression free survival rates in GCB were higher than NON-GCB, but without statistical difference (88.2±4.2%vs70.6±8.4%; P=0.580;79.6±5.8%, vs54.1±7.8%; P=0.096; respectively).Chemotherapy can make HBsAg-positive group and HBsAg-negative group with hepatitis incidence increased (17.7%vs39.2%, P=0.0027) and (4.4%vs30.1%, P0.001). Whether in HBsAg-positive group or HBsAg-negative group, rituximab and chemotherapy can increase the incidence of hepatitis (positive group45.9%vs33.3%; negative group,34.7%vs20.0%), but the difference was not statistically significance for positive group (P=0.252), negative group difference was statistically significant (P=0.0319).Conclusion When compared with CHOP alone, combination of rituximab to the CHOP significantly increases the complete response rates, the overall response rates, progression free survival rates and overall survival rates, without statistical difference in progression free survival rates and overall survival rates between GCB group and NON-GCB group.Chemotherapy can make HBsAg-positive group and HBsAg-negative with increased hepatitis incidence. Whether in HBsAg-positive group or HBsAg-negative group, rituximab and can increase the chemotherapy incidence of hepatitis, but positive group difference was not statistically significant, negative group, the difference was statistically significant. Part5Prognostic value of interim FDG PET/CT in diffuse large B-cell lymphomaAbstractObjectives Evaluate the interim PET-CT’s prognostic value for diffuse large B cell lymphoma (DLBCL).Methods A total of37in-patients diagnosed with DLBCL between January2008and August2014were included in this non-randomized retrospective study. All patients received PET-CT scan before and interim chemotherapy. According to the change in the PET-CT SUV values, we divide samples into two different groups and comparison between groups’ progression-free survival (PFS) and overall survival (OS).Results Based on the change in the PET-CT SUV values, we divided all samples into two groups as PET(-) and PET(+) by different standards. When defined ΔSUVMAX>70%as PET(-), the5-year PFS were47.7±12.9%and64.1±.1%in PET(-) and PET(+) with no statistical difference (P=0.112), the5-year OS were58.9±14.9%and76.0±10.9%in PET(-) and PET(+) with no statistical difference (P=0.360). When defined ΔSUVMAX≥90%as PET(-), the5-year PFS were49.3±11.3%and80.0±17.9%in PET(-) and PET(+) with statistical difference (P<0.05), the5-year OS were57.3±12.5%and88.9±10.5%in PET(-) and PET(+) with statistical difference (P＜0.05). When defined SUVMAX value absolute decrease≥3.2as PET(-), the5-year PFS were41.3±12.1%and85.7±13.2%in PET(-) and PET(+) with statistical difference (P＜0.05), the5-year OS were61.3±11.6%and83.1±11.0%in PET(-) and PET(+) with statistical difference (P＜0.05).Conclusion When defined ΔSUVMAX≥90%or SUVMAX value absolute decrease≥3.2as PET(-), OS and PFS in group PET(-) was better than group PET(+).When defined ΔSUVMAX≥70%as PET(-), there was no statistical difference between groups. |
PDF Full Text Request